What is the recommended tapering schedule for a patient taking Cymbalta (duloxetine) 60 mg for 6 months?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 10, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Tapering Schedule from Cymbalta 60 mg After 6 Months

For a patient taking duloxetine 60 mg for 6 months in an outpatient setting, reduce to 30 mg daily for 2-4 weeks, then discontinue completely, with close monitoring for withdrawal symptoms at each step. 1, 2

Outpatient Tapering Protocol

Initial Dose Reduction

  • Reduce from 60 mg to 30 mg once daily and maintain this dose for a minimum of 2-4 weeks before considering complete discontinuation 1
  • The FDA label recommends gradual dose reduction rather than abrupt cessation to minimize withdrawal symptoms 2
  • This represents a 50% reduction, which is more conservative than inpatient protocols but appropriate for outpatient management where continuous monitoring is not available 1

Critical Distinction: Outpatient vs Inpatient Tapering

  • Outpatient tapers should be slower than the 1-2 week inpatient protocol due to lack of continuous monitoring 1
  • While inpatient settings can implement faster tapers (30 mg for 1-2 weeks before discontinuation), outpatient protocols recommend 10% reductions every 2-4 weeks over 2-12 months for maximum safety 1
  • Given your patient has only been on duloxetine for 6 months (relatively short duration), the moderate approach of 30 mg for 2-4 weeks is reasonable 1

Monitoring for Withdrawal Symptoms

Expected Withdrawal Timeline and Symptoms

  • Withdrawal symptoms typically emerge within days of dose reduction and include dizziness, nausea, headache, paresthesia, irritability, insomnia, anxiety, and hyperhidrosis 1, 2
  • Nausea and dizziness are the most common withdrawal symptoms 1
  • Physical symptoms like dizziness and paresthesia help distinguish withdrawal from relapse of the underlying condition 1

Follow-Up Schedule

  • Schedule appointments every 1-2 weeks during the taper to assess for withdrawal symptoms and monitor for return of the original condition being treated 3
  • Document symptom severity at each visit to guide subsequent taper adjustments 1

Managing Withdrawal Symptoms

If Withdrawal Symptoms Occur

  • Return to the previous well-tolerated dose (60 mg) if severe withdrawal symptoms emerge 1, 3
  • After stabilization, attempt a slower taper with the time between dose reductions extended to 3-4 weeks 3
  • Consider maintaining 30 mg for an additional 1-2 weeks before attempting discontinuation if mild withdrawal symptoms occur 1

Symptomatic Management Options

  • For nausea: Use antiemetics as needed 1
  • For insomnia: Consider short-term non-benzodiazepine sleep aids 1
  • For muscle aches: NSAIDs or acetaminophen 1
  • For anxiety: Non-pharmacologic interventions should be first-line 1

Critical Caveats

Avoid Alternate-Day Dosing

  • Never use alternate-day dosing as a tapering strategy for duloxetine, as this causes pronounced receptor occupancy variation and significantly increases withdrawal risk 4
  • Duloxetine's elimination half-life makes every-other-day dosing particularly problematic for maintaining stable drug levels 4

Food Considerations During Taper

  • Taking duloxetine with food can improve tolerability, particularly when starting at higher doses or if the patient experiences nausea 5
  • This may be especially helpful during the initial dose reduction phase 5

Before Complete Discontinuation

  • Ensure alternative management strategies are in place for the original indication (depression, anxiety, pain, etc.) before complete discontinuation to prevent symptom recurrence 1
  • Verify that the indication for duloxetine has resolved or that another treatment plan is established 1

References

Guideline

Tapering Duloxetine in an Inpatient Setting

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Mirtazapine Tapering Protocol

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.